Market-based licensing for HPV vaccines in developing countries

Health Affairs

Volumn 27, Issue 1, 2008, Pages 130-139

  Outterson, Kevin ^a   Kesselheim, Aaron S ^b  

^a BOSTON UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; OSELTAMIVIR; WART VIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMIC ASPECT; ECONOMICS; FEE; FEMALE; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; INCOME; LEGAL ASPECT; LICENSING; MARKET; PRACTICE GUIDELINE; REVIEW; UTERINE CERVIX CANCER;

DEVELOPING COUNTRIES; DRUG INDUSTRY; ECONOMIC COMPETITION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LICENSURE; PAPILLOMAVIRUS VACCINES; PRESCRIPTION FEES; RESEARCH SUPPORT AS TOPIC;

EID: 38849131411     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.27.1.130     Document Type: Review

References (58)

1. F. Kamangar, G.M. Dores, and W.F. Anderson, "Patterns of Cancer Incidence, Mortality, and Prevalence across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World," Journal of Clinical Oncology 24, no. 14 (2006): 2137-2150.
2. R. Sankaranarayanan, A.M. Budukh, and R. Rajkumar, "Effective Screening Programmes for Cervical Cancer in Low- and Middle-Income Developing Countries," Bulletin of the World Health Organization 79, no. 10 (2001): 954-962.
3. World Health Organization, "Revised Global Burden of Disease (GBD): 2002 Estimates," 2004, http://www.who.int/healthinfo/bodgbd2002revised/en (accessed 2 October 2007).
4. X. Castellsague et al., "Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention," Journal of the National Cancer Institute 98, no. 5 (2006): 303-315.
5. S.M. Garland et al., "Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases," New England Journal of Medicine 356, no. 19 (2007): 1928-1943.
6. R.A. Charo, "Politics, Parents, and Prophylaxis - Mandating HPV Vaccination in the United States," New England Journal of Medicine 356, no. 19 (2007): 1905-1908.
7. A. Batson, F. Meheus, and S. Brooke, "Chapter 26: Innovative Financing Mechanisms to Accelerate the Introduction of HPV Vaccines in Developing Countries," Vaccine 24, no. 3 Supp. (2006): s219-s225; and J.M.
8. Agosti and S.J. Goldie, "Introducing HPV Vaccine in Developing Countries - Key Challenges and Issues," New England Journal of Medicine 356, no. 19 (2007): 1908-1910.
9. K. Outterson, "Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets," Yale Journal of Health Policy, Law, and Ethics 5, no. 1 (2005): 193-291.
10. F.M. Scherer, "A Note on Global Welfare in Pharmaceutical Patenting," World Economy 27, no. 7 (2004): 1127-1142;
11. and World Bank, "HNP Group Data: Low and Middle Income," 2004, http://devdata.worldbank.org/hnpstats/HNPSummary/groupData/GetShowData.asp? sCtry=LMY (accessed 14 August 2007).
12. WHO, "Equitable Access to Essential Medicines: A Framework for Collective Action," in WHO Policy Perspectives on Medicines (Geneva: WHO, 2004).
13. J. Tanne, "CDC Recommends Expensive Vaccine for All Girls Aged 11-12," British Medical Journal 333, no. 7559 (2006): 114.
14. S.J. Goldie et al., "Projected Clinical Benefits and Cost-Effectiveness of a Human Papillomavirus 16/18 Vaccine," Journal of the National Cancer Institute 96, no. 8 (2004): 604-615.
15. S.J. Goldie et al., "Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries," New England Journal of Medicine 353, no. 20 (2005): 2158-2168.
16. S.J. Goldie et al., "Cost-Effectiveness of HPV 16, 18 Vaccination in Brazil," Vaccine 25, no. 33 (2007): 6257-6270.
17. P.J. Hammer, "Differential Pricing of Essential AIDS Drugs: Markets, Politics, and Public Health," Journal of International Economic Law 5, no. 4 (2002): 883-912.
18. A. Batson, "The Problems and Promise of Vaccine Markets in Developing Countries," Health Affairs 24, no. 3 (2005): 690-693.
19. R. Twombly, "U.S. Girls to Receive HPV Vaccine but Picture Unclear on Potential Worldwide Use, Acceptance," Journal of the National Cancer Institute 98, no. 15 (2006): 1030-1032.
20. Bill and Melinda Gates Foundation, "Cervical Cancer Vaccine Project," Press Release, October 2006, http://www.path.org/files/ RH_cc_vacc_proj_fs_update.pdf (accessed 2 October 2007).
21. Médicins sans Frontières, "Gilead's Tenofovir 'Access Program' for Developing Countries: A Case of False Promises?" Press Release, 7 February 2006, http://www.doctorswithoutborders.org/pr/2006/02-07- 2006.cfm (accessed 2 October 2007).
22. M.A. Friedman, H. den Besten, and A. Attaran, "Out-Licensing: A Practical Approach for Improvement of Access to Medicines in Poor Countries," Lancet 361, no. 9354 (2003): 341-344.
23. C.V. Chien, "HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?" PLoS ONE 2, no. 3 (2007): e278.
24. M. Kremer and R. Glennerster, Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases (Princeton, N.J.: Princeton University Press, 2004);
25. and E.R. Berndt and J.A. Hurvitz, "Vaccine Advance-Purchase Agreements for Low-Income Countries: Practical Issues," Health Affairs 24, no. 3 (2005): 653-665.
26. D.W. Light, "Is G8 Putting Profits Before the World's Poorest Children?" Lancet 370, no. 9584 (2007): 297-298.
27. A. Kapczynski et al., "Addressing Global Health Inequities: An Open Licensing Approach for University Innovations," Berkeley Technology Law Journal 20, no. 2 (2005): 1031-1114;
28. and Universities Allied for Essential Medicines, "Model Provisions for an 'Equitable Access and Neglected Disease License'," http://www.essentialmedicine.org/EAL.pdf (accessed 2 October 2007).
29. E. Check, "Universities Urged to Do More for Poor Nations," Nature 444, no. 7118 (2006): 412-413.
30. A.S. Kesselheim and J. Avorn, "Biomedical Patents and the Public's Health: Is There a Role for Eminent Domain?" Journal of the American Medical Association 295, no. 4 (2006): 434-437;
31. and J.P. Love, "Recent Examples of the Use of Compulsory Licenses on Patents," Knowledge Ecology International Research Note 2, 8 March 2007, http://www.keionline.org/misc-docs/recent_cls.pdf (accessed 3 October 2007).
32. Agreement on Trade-Related Aspects of Intellectual Property Rights, April 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, art. 31(b), Legal Instruments - Results of the Uruguay Round, vol. 31, 33 I.L.M. 81 (1994).
33. R. Steinbrook, "Thailand and the Compulsory Licensing of Efavirenz," New England Journal of Medicine 356, no. 6 (2007): 544-546.
34. L. Abboud, "Abbott Labs Lowers Brazil's Price for AIDS Drug, Ending Standoff," Wall Street Journal, 11 July 2005;
35. and C.W. Dugger, "Brazil Overrides Merck Patent on AIDS Drug," Wall Street Journal, 5 May 2007.
36. J.P. Love, Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies, Health Economics and Drugs, TCM Series no. 18, Pub. no. WHO/TCM/2005.1, 2005, http://www.who.int/medicines/areas/ technical_cooperation/WHOTCM2005.1_OMS.pdf (accessed 3 October 2007).
37. "Bangkok's Drug War Goes Global" (editorial), Wall Street Journal, 7 March 2007;
38. and M. Vaughan, "In Clash with Activists, Critics Charge Thailand Violation of Trade Rules," Intellectual Property Watch, 19 March 2007.
39. MSF, "Abbott Should Reconsider Its Unacceptable Decision to Not Sell New Medicines in Thailand," Press Release, 23 March 2007, http://accessmed-msf.org/prod/publications.asp?scntid=2332007121275& contenttype=PARA&(accessed 25 October 2007).
40. Office of the United States Trade Representative, 2007 Special 301 Report, 2007, p. 27, http://www.ustr.gov/assets/Document_Library/ Reports_Publications/2007/2007_Special_301_Review/asset_upload_file230_11122. pdf (accessed 3 October 2007).
41. Sean M. Flynn, associate professor, American University Washington College of Law, "Access to Medicines Issues in the U.S.-Korea Free Trade Negotiations," Testimony before the House Ways and Means Subcommittee on Trade, March 2007.
42. K. Outterson, "Agony in the Antipodes: The Generic Drug Provisions in the Australia-U.S. Free Trade Agreement," Journal of Generic Medicines 2, no. 4 (2005): 316-326.
43. Scherer, "A Note on Global Welfare." 37. Families USA, "Profiting from Pain: Where Prescription Drug Dollars Go" (Washington: Families USA, 2002).
44. K. Outterson, "Patent Buy-Outs for Global Disease Innovations for Low- and Middle-Income Countries," American Journal of Lawand Medicine 32, no. 2-3 (2006): 159-173;
45. and P. Stein and E. Valery, "Competition: An Antidote to the High Price of Prescription Drugs," Health Affairs 23, no. 4 (2004): 151-158.
46. Merck and Co., Form 10-K (31 December 2005).
47. Calculated as follows: $2 billion (estimated global market for Gardasil) x 0.075 (estimated low- and middle-income market size for Merck) x 0.11 (estimated R&D percentage of revenues) = $16.5 million.
48. To simplify administration of royalties, net income could be deemed to be actual net GO License revenues less the marginal cost of production. A handy proxy for marginal cost is the lowest sustained generic price by any producer in any market. See Outterson, "Patent Buy-Outs."
49. S. Chaifetz et al., "Closing the Access Gap for Health Innovations: An Open Licensing Proposal for Universities," Globalization and Health 3, no. 1 (2007): 1.
50. L.H. Glantz and G.J. Annas, "Research in Developing Countries: Taking 'Benefit' Seriously," Hastings Center Report 28, no. 6 (1998): 38-42.
51. WHO, Public Health: Innovation and Intellectual Property Rights, 2006, pages?, http://www.who.int/intellectualproperty/documents/thereport/ ENPublicHealthReport.pdf (accessed 2 October 2007).
52. D.G. McNeil Jr., "Indian Company to Make Generic Version of Flu Drug Tamiflu," New York Times, 14 October 2005.
53. Knowledge Ecology International, The Essential Medical Inventions Licensing Agency, 1 June 2007 http://www.keionline.org/misc-docs/emila.pdf (accessed 16 August 2007).
54. Council Regulation 953/2003, "To Avoid Trade Diversion into the European Union of Certain Key Medicines," 2003 O.J. (L 135/5-9): art. 7.
55. WTO General Council, "Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health," WT/L/540 and Corr.1, 1 September 2003, http://www.wto.org/english/tratop_e/trips_e/implem_para6_e. htm (accessed 17 September 2007).
56. S. Boseley and R. Carroll, "Profiteers Resell Africa's Cheap AIDS Drugs," Guardian, 4 October 2002.
57. Glaxo Group Ltd. v. Dowelhurst Ltd., [2004] E.T.M.R. 39 (31 July 2003), 2003 WL 21729286.
58. K. Outterson and R. Smith, "Counterfeit Drugs: The Good, the Bad, and the Ugly," Albany Law Journal of Science and Technology 16, no. 3 (2006): 525-543.